MiMedx Group (MDXG) Competitors

MiMedx Group (NASDAQ:MDXG) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.

Which has stronger valuation & earnings, MDXG or XENT?

MiMedx Group has higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$340.46M	2.70	$58.23M	$0.44	14.16
Intersect ENT	$106.75M	8.95	-$159.63M	-$4.79	-5.90

Does the MarketBeat Community favor MDXG or XENT?

Intersect ENT received 364 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 80.77% of users gave MiMedx Group an outperform vote while only 59.01% of users gave Intersect ENT an outperform vote.

Company	Underperform	Outperform
MiMedx Group	Outperform Votes 42 80.77%	Underperform Votes 10 19.23%
Intersect ENT	Outperform Votes 406 59.01%	Underperform Votes 282 40.99%

Is MDXG or XENT more profitable?

MiMedx Group has a net margin of 23.63% compared to Intersect ENT's net margin of -161.94%. MiMedx Group's return on equity of 34.24% beat Intersect ENT's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	23.63%	34.24%	18.20%
Intersect ENT	-161.94%	-709.52%	-48.18%

Do institutionals and insiders hold more shares of MDXG or XENT?

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 92.5% of Intersect ENT shares are held by institutional investors. 1.3% of MiMedx Group shares are held by company insiders. Comparatively, 2.1% of Intersect ENT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate MDXG or XENT?

MiMedx Group presently has a consensus target price of $12.00, indicating a potential upside of 92.62%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than Intersect ENT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Intersect ENT	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media favor MDXG or XENT?

In the previous week, MiMedx Group had 3 more articles in the media than Intersect ENT. MarketBeat recorded 3 mentions for MiMedx Group and 0 mentions for Intersect ENT. MiMedx Group's average media sentiment score of 0.87 beat Intersect ENT's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Overall Sentiment
MiMedx Group	Positive
Intersect ENT	Neutral

Which has more risk and volatility, MDXG or XENT?

MiMedx Group has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.

Summary

MiMedx Group beats Intersect ENT on 13 of the 17 factors compared between the two stocks.